ArticleCancer medicine2026
Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBiliary tract cancer (BTC) represents a heterogeneous disease with highly lethal malignancy and poor clinical outcomes. Here, we aimed to evaluate its genomic profiles to promote the development of precision medicine for BTC. MATERIALS AND
methodsGenomic analysis of 134 BTC patients was performed by using targeted panel sequencing in this study. The results of genomic testing were analyzed by integrating patients' clinicopathologic data, including treatment information and clinical outcomes. The significance of genetic alterations in our cohort was compared with western BTCs by using public repositories NGS data from ICGC cohort.
resultsThe most frequent genomic alterations were TP53 (55.5%), KRAS (38.1%), ARID1A (17.2%), and CDKN2A (15.7%) in our cohort. Notably, Chinese BTC patients had a higher prevalence of TP53, KRAS, and LRP1B alterations compared with Western BTCs. Moreover, a higher frequency of IDH and FGFR2 alterations was found in intrahepatic cholangiocarcinoma (ICA), whereas BRIP1, KRAS, and POLE alterations were more likely to accumulate in extrahepatic cholangiocarcinoma (ECA), and those with gallbladder carcinoma (GBC) had a higher prevalence of NF1, MSH3, and PIK3R1 alterations. Furthermore, several genomic alterations were observed to have a significant impact on progression-free survival (PFS) and overall survival (OS) in our cohort. NGS data from the ICGC cohort further validated that TP53 was associated with inferior clinical outcomes both in Chinese and Western BTC patients, regardless of histopathologic subtypes or therapeutic approaches.
conclusionWe demonstrated the real-world genomic characteristics of BTC patients, which may have promising implications for the development and application of precision medicine in the future. Well-designed prospective studies are mandatory to validate the predictive role of significant genomic alterations observed in our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.